IL-33

IL-33 Overview

English NameInterleukin-33Approved Drugs0
Drugs in Clinical Trials9Target SynonymNuclear Factor For High Endothelial Venules,DVS27-Related Protein,IL1F11,IL33,Interleukin-1 family member 11,IL-1F11,Interleukin 33,Nuclear Factor From High Endothelial Venules,C9orf26,NF-HEV,Chromosome 9 Open Reading Frame 26 (NF-HEV),Interleukin-1 Family, Member 11,NFEHEV,DVS27,IL-33,NFHEV,Interleukin-33,DKFZp586H0523
Highest Development StagePhase 3 Clinical
English NameInterleukin-33
Target SynonymNuclear Factor For High Endothelial Venules,DVS27-Related Protein,IL1F11,IL33,Interleukin-1 family member 11,IL-1F11,Interleukin 33,Nuclear Factor From High Endothelial Venules,C9orf26,NF-HEV,Chromosome 9 Open Reading Frame 26 (NF-HEV),Interleukin-1 Family, Member 11,NFEHEV,DVS27,IL-33,NFHEV,Interleukin-33,DKFZp586H0523
Approved Drugs0
Drugs in Clinical Trials9
Highest Development StagePhase 3 Clinical

IL-33 Background

Interleukin 33 (IL33) is known as C9orf26, DKFZp586H0523, DVS27, NF-HEV, NFEHEV, RP11-575C20.2,and is a cytokine belonging to the IL-1 superfamily. IL-33 induces helper T cells, mast cells, eosinophils and basophils to produce type 2 cytokines. IL-33 mediates its biological effects by interacting with the receptors ST2 (aka IL1RL1) and IL-1 Receptor Accessory Protein (IL1RAP), activating intracellular molecules in the NF-κB and MAP kinase signaling pathways that drive production of type 2 cytokines (e.g. IL-5 and IL-13) from polarized Th2 cells. In vivo, IL-33 induces the expression of IL-4, IL-5, and IL-13 and leads to severe pathological changes in mucosal organs.

IL-33 Synonyms

IL33,DV27,C9ORF26,IL1F11,NFHEV,DKFZp586H0523,DVS27,NFEHEV,RP11-575C20.2

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
TozorakimabMEDI-3506Phase 3 ClinicalMedimmuneAsthma; Bronchitis, Chronic; Dermatitis, Atopic; Diabetic Nephropathies; Pneumonia, Viral; Pulmonary Disease, Chronic Obstructive
Details
ItepekimabREGN-3500; SAR-440340Phase 3 ClinicalRegeneron Pharmaceuticals Inc, SanofiAsthma; Bronchiectasis; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis, Atopic; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Sinusitis
Details
EtokimabANB-020Phase 2 ClinicalAnaptysbio IncAsthma; Dermatitis, Atopic; Hypersensitivity; Peanut Hypersensitivity; Pulmonary Eosinophilia; Sinusitis
Details
MT-2990MT-2990Phase 2 ClinicalMitsubishi Tanabe Pharma CorpEndometriosis; Pain; Rhinitis, Allergic, Seasonal; Vasculitis
Details
GSK-3862995GSK-3862995B; GSK3862995; GSK-3862995; GSK3862995BPhase 2 ClinicalGlaxosmithkline PlcBronchiectasis; Pulmonary Disease, Chronic Obstructive
Details
OmpekimigPF-07264660Phase 2 ClinicalPfizer IncDermatitis, Atopic
Details
SSGJ-621SSGJ-621; 621Phase 1 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co LtdAsthma; Pulmonary Disease, Chronic Obstructive
Details
CAN-10CAN-10Phase 1 ClinicalLund University FoundationMyocarditis; Plaque psoriasis; Scleroderma, Systemic
Details
QX-007NQX-007NPhase 1 ClinicalQyuns Therapeutics Co LtdAsthma; Pulmonary Disease, Chronic Obstructive
Details

Product Reviews

  • 1***62019-09-26
    1People Like
    I used this protein to explore and establish experimental methods to do antibody screening. The experimental methods that I used include Elisa, flow cytometry, octet determination of antibody binding and competition experiments. The protein works well, the experiments results met my expectations. I buy ACRO's protein frequently.
  • Overview
  • Product List
  • Product Reviews
  • Clinical Drug Information